Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt över 249 kr.
Beskrivning
In the past few years, antisense methodology has moved from in vitro studies to in vivo studies and first human trials. The work is organized into three sections: antisense application in vitro, antisense application in vivo (animal models) and finally, clinical antisense studies.
Gunther Hartmann, M.D. is a clinical and research fellow at the Division of Clinical Pharmacology, University of Munich.Stefan Endres, M.D. is an internist with subspecialties in gastroenterology and intensive care medicine. He is Chief of the Division of Clinical Pharmacology of the medical faculty at the University of Munich.
Innehållsförteckning
I: The chemistry of antisense oligonucleotides.- 1. Chemical synthesis and purification of phosphorothioate antisense oligonucleotides.- 2. How to choose optimal antisense targets in an mRNA.- II: Antisense application in vitro.- 3. How to characterize and improve oligonucleotide uptake into leukocytes.- 4. Strategies for targeted uptake of antisense oligonucleotides in hepatocytes.- 5. How to exclude immunostimmulatory and other nonantisense effects of antisense oligonucleotides.- 6. Testing antisense oligonucleotides in controlled cell culture assays.- 7. Inhibition of TNF synthesis by antisense oligonucleotides.- 8. Inhibition of IGF-1 receptor expression by antisense oligonucleotides in vitro and in vivo.- III: Antisense application in vivo.- 9. How to test antisense oligonucleotides in animals.- 10. Lipid-based carriers for the systemic delivery of antisense drugs.- 11. Designing a clinical antisense study.
